Evidence map›Paper›PMID 19270784›Full record

ArticleEnvironmental health perspectives2009

Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells.

Elizabeth W Lapensee, Traci R Tuttle, Sejal R Fox, Nira Ben-Jonathan

Open access · diamondAbstract read
In one paragraph

Article in Environmental health perspectives, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 134 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Can Exposure to Environmental Pollutants Be Associated with Less Effective Chemotherapy in Cancer Patients?International journal of environmental research and public health · 2022
    Review
  14. Review
  15. Review
  16. Environmental chemicals, breast cancer progression and drug resistance.Environmental health : a global access science source · 2020
    Review
  17. Article
  18. Article
  19. Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Elizabeth W LapenseeDepartment of Cancer and Cell Biology, University of Cincinnati, Cincinnati, Ohio 45267-0521, USA. Nira.Ben-Jonathan@uc.edu
Traci R Tuttle
Sejal R Fox
Nira Ben-Jonathan
University of Cincinnati · US

Funding

ENVIRONMETAL CARCINOGENESIS AND MUTAGENESIST32ES007250 · NIEHS · UNIVERSITY OF CINCINNATI · PI MILLER, WILLIAM E · 1988 to 2024
$11.9M
Prolactin as a Growth Factor in Breast CancerR01CA096613 · NCI · UNIVERSITY OF CINCINNATI · PI BEN-JONATHAN, NIRA · 2004 to 2013
$2.7M
GENETIC ANALYSIS OF MULTIDRUG RESISTANCE GENESZ01BC005725 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DEAN, MICHAEL · 1996 to 2008
$1.9M
Xenoestrogens: Genomic and Non-genomic MechanismsR01ES012212 · NIEHS · UNIVERSITY OF CINCINNATI · PI BEN-JONATHAN, NIRA · 2003 to 2006
$1.1M
Intramural NIH HHS Z01 BC005725NCI NIH HHS CA096613NCI NIH HHS R01 CA096613NIEHS NIH HHS 5T32ES007250NIEHS NIH HHS ES012212NIEHS NIH HHS R01 ES012212NIEHS NIH HHS T32 ES007250
6 · The paper itself

Abstract

backgroundResistance to chemotherapy is a major problem facing breast cancer patients, and identifying potential contributors to chemoresistance is a critical area of research. Bisphenol A (BPA) has long been suspected to promote carcinogenesis, but the high doses of BPA used in many studies generated conflicting results. In addition, the mechanism by which BPA exerts its biological actions is unclear. Although estrogen has been shown to antagonize anticancer drugs, the role of BPA in chemoresistance has not been examined.

objectiveThe objective of our study was to determine whether BPA at low nanomolar concentrations opposes the action of doxorubicin, cisplatin, and vinblastine in the estrogen receptor-alpha (ERalpha)-positive T47D and the ERalpha-negative MDA-MB-468 breast cancer cells.

methodsWe determined the responsiveness of cells to anticancer drugs and BPA using the 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) cytotoxicity assay. Specific ERalpha and ERbeta inhibitors and real-time polymerase chain reaction were used to identify potential receptor(s) that mediate the actions of BPA. Expression of antiapoptotic proteins was assessed by Western blotting.

resultsBPA antagonizes the cytotoxicity of multiple chemotherapeutic agents in both ERalpha-positive and -negative breast cancer cells independent of the classical ERs. Both cell types express alternative ERs, including G-protein-coupled receptor 30 (GPR30) and members of the estrogen-related receptor family. Increased expression of antiapoptotic proteins is a potential mechanism by which BPA exerts its anticytotoxic effects.

conclusionsBPA at environmentally relevant doses reduces the efficacy of chemotherapeutic agents. These data provide considerable support to the accumulating evidence that BPA is hazardous to human health.

Indexed as

ApoptosisBenzhydryl CompoundsBisphenol A CompoundsBlotting, WesternBreast NeoplasmsCell Line, TumorCisplatinDose-Response Relationship, DrugDoxorubicinDrug InteractionsDrug ResistanceEstradiolEstrogen Receptor alphaFulvestrantHumansPhenolsBenzhydryl Compoundsbisphenol ABisphenol A CompoundsCisplatinDoxorubicinEstradiolEstrogen Receptor alphaFulvestrantPhenolsVinblastinebisphenol Abreast cancer cellschemotherapeutic agentscytotoxicityestrogen receptors

Identifiers

PMID19270784
PMCPMC2649216
OpenAlexW1996193517

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.